Tivic CEO Michael Handley Sends Letter to Shareholders, Focuses on Biopharmaceuticals
Tivic CEO Michael Handley sent a letter to shareholders, which said in part, "As I assume the role of CEO at Tivic, my immediate priority is to establish a transparent dialogue with you regarding our current standing, our strategic pivot, and the long-term vision we are executing. First, I want to thank the Board of Directors for their confidence and support. Some of you recognize me from my time as CEO of Statera Biopharma, where I led the advancement of Entolimod, our Toll-like Receptor 5 agonist. Over the past year, as Tivic's COO and President of Biopharma, I have continued to advance the program strategically and operationally. Tivic is now a biopharmaceutical company solely focused on the Entolimod and our TLR5 platform with our second-generation TLR5 molecule, Entolasta. To maximize our impact and resources, we have made the deliberate decision to discontinue commercial sales of the ClearUP sinus device and suspend development of the non-invasive vagus nerve stimulation platform. While those assets remain the property of the company, we have made the deliberate decision to concentrate our resources on the significant opportunity represented by our biotherapeutic programs. With our pivot into biopharmaceuticals, we are aggressively pursuing the multi-billion-dollar oncology market. Entolimod's mechanism of action shows significant potential in preventing cell death in bone marrow and gastrointestinal epithelial tissues thereby addressing conditions like neutropenia, which affects up to half of all cancer patients, and radiation-induced mucosal necrosis. While we are currently developing the injectable form, we are also exploring oral formulations to significantly broaden our clinical applications.A primary pillar of our corporate strategy is our collaboration with the Biomedical Advanced Research and Development Authority. Following our second meeting with the agency two weeks ago, we are encouraged by our progress. Our objective is to secure BARDA funding to advance Entolimod as a medical countermeasure for Acute Radiation Syndrome. We believe Entolimod's highly differentiated profile makes it a superior candidate for the Strategic National Stockpile compared to existing treatments. In parallel, we are engaging with allied governments interested in independent stockpiling for their own national preparedness programs. Our speed is driven by our vertical integration. Through Velocity Bioworks, our wholly owned Contract Development & Manufacturing Organization or CDMO, we successfully demonstrated a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation. This milestone was achieved on time and within budget, meeting all purity and potency specifications. Controlling our domestic supply chain is not only an operational advantage but a critical requirement for U.S. government procurement. Tivic is uniquely positioned at the intersection of critical macro trends: the urgent need for national preparedness, the demand for domestic biomanufacturing, and an investor preference for scalable, high value assets. By combining late-stage therapeutics with in-house manufacturing, we are building a profit center designed to serve both our internal pipeline and the broader biotech industry. We will provide a comprehensive update during our year-end call tomorrow, March 25, held in conjunction with our Form 10-K filing. I look forward to speaking with you then."
Trade with 70% Backtested Accuracy
Analyst Views on TIVC
About TIVC
About the author
Tivic Health Systems Reports FY 2025 Financial Overview
- Rising Operating Expenses: Tivic Health's operating expenses for FY 2025 are projected to reach $7.9 million, significantly up from $4.5 million in 2024, indicating ongoing investments in business expansion and R&D that may pressure short-term profitability.
- Increased Net Loss: The expected net loss for 2025 is between $8.8 million and $9.1 million, compared to $5.7 million in 2024, raising concerns among investors regarding the company's financial health, which could negatively impact stock performance.
- Improved Cash Position: The company anticipates cash and working capital of $12.6 million and $12.4 million in 2025, a substantial increase from $2.0 million in 2024, reflecting positive progress in cash management and liquidity that supports future operations and investments.
- Market Opportunity Outlook: Following its strategic transformation, Tivic Health has identified a $20 billion oncology market opportunity, indicating potential for expansion into new market segments that could lay the groundwork for future growth.
Tivic Health Transforms into Immunotherapy Company
- Strategic Transformation: Under CEO Michael Handley's leadership, Tivic Health has fully pivoted to immunotherapy, focusing on the TLR5 platform with candidates like Entolimod and Entolasta, targeting the oncology supportive care market projected to grow from $15 billion to $20 billion.
- In-House Manufacturing: The company has completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to provide cost efficiencies and a new revenue stream, significantly reducing development timelines and costs for Entolimod while enhancing supply chain control.
- Improved Financial Position: As of December 31, 2025, Tivic's cash and cash equivalents totaled $12.6 million, a substantial increase from $2 million in 2024, indicating improved financial health following new business lines and acquisitions.
- Market Opportunities: Tivic is actively engaging with U.S. government agencies for potential biodefense contracts and plans to initiate clinical trials for Entolimod within the year, showcasing the company's strong potential and readiness in the biotherapeutics market.
TIVIC HEALTH SYSTEMS INC - MAKES PROGRESS ON ENTOLIMOD PLATFORM FOR POSSIBLE FUNDING PARTNERSHIPS
- Advancements in Health Systems: Tivic Health Systems continues to make progress in enhancing its health technology platform.
- Focus on Funding Partnerships: The company is actively seeking potential funding partnerships to support its growth and development initiatives.
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
Tivic Grows Its Intellectual Property Assets
New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.
Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.
Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.
Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.
Tivic Health Scheduled to Announce Third Quarter 2025 Financial Results on November 14th Through Conference Call and Webcast
Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.
Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.
Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.
Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.
Tivic Health Systems Reports FY 2025 Financial Overview
- Rising Operating Expenses: Tivic Health's operating expenses for FY 2025 are projected to reach $7.9 million, significantly up from $4.5 million in 2024, indicating ongoing investments in business expansion and R&D that may pressure short-term profitability.
- Increased Net Loss: The expected net loss for 2025 is between $8.8 million and $9.1 million, compared to $5.7 million in 2024, raising concerns among investors regarding the company's financial health, which could negatively impact stock performance.
- Improved Cash Position: The company anticipates cash and working capital of $12.6 million and $12.4 million in 2025, a substantial increase from $2.0 million in 2024, reflecting positive progress in cash management and liquidity that supports future operations and investments.
- Market Opportunity Outlook: Following its strategic transformation, Tivic Health has identified a $20 billion oncology market opportunity, indicating potential for expansion into new market segments that could lay the groundwork for future growth.
Tivic Health Transforms into Immunotherapy Company
- Strategic Transformation: Under CEO Michael Handley's leadership, Tivic Health has fully pivoted to immunotherapy, focusing on the TLR5 platform with candidates like Entolimod and Entolasta, targeting the oncology supportive care market projected to grow from $15 billion to $20 billion.
- In-House Manufacturing: The company has completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to provide cost efficiencies and a new revenue stream, significantly reducing development timelines and costs for Entolimod while enhancing supply chain control.
- Improved Financial Position: As of December 31, 2025, Tivic's cash and cash equivalents totaled $12.6 million, a substantial increase from $2 million in 2024, indicating improved financial health following new business lines and acquisitions.
- Market Opportunities: Tivic is actively engaging with U.S. government agencies for potential biodefense contracts and plans to initiate clinical trials for Entolimod within the year, showcasing the company's strong potential and readiness in the biotherapeutics market.
TIVIC HEALTH SYSTEMS INC - MAKES PROGRESS ON ENTOLIMOD PLATFORM FOR POSSIBLE FUNDING PARTNERSHIPS
- Advancements in Health Systems: Tivic Health Systems continues to make progress in enhancing its health technology platform.
- Focus on Funding Partnerships: The company is actively seeking potential funding partnerships to support its growth and development initiatives.
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
Tivic Grows Its Intellectual Property Assets
New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.
Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.
Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.
Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.
Tivic Health Scheduled to Announce Third Quarter 2025 Financial Results on November 14th Through Conference Call and Webcast
Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.
Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.
Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.
Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.
